Mabion receives FDA confirmation for Pre-IND Type B meeting
Mabion said the FDA confirmed a Pre-IND Type B meeting for MabionCD20, seeking orphan drug status in ITP.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.